| pubmed-article:19888784 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0066814 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0026549 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0242402 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C1706077 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0150097 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0439655 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0355800 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0037633 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C1696465 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C1382100 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C0991505 | lld:lifeskim |
| pubmed-article:19888784 | lifeskim:mentions | umls-concept:C2934985 | lld:lifeskim |
| pubmed-article:19888784 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:19888784 | pubmed:dateCreated | 2009-11-5 | lld:pubmed |
| pubmed-article:19888784 | pubmed:abstractText | Given the dual public health challenges of undertreated pain and opioid abuse, there is a need to reduce attractiveness of opioid analgesics to drug abusers. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules, indicated for treatment of chronic, moderate to severe pain, contain polymer-coated pellets of morphine, each with a core of sequestered naltrexone intended for release only upon tampering (crushing). The purpose of this study was to assess the pharmacodynamic effects (including drug-liking and euphoria) of whole and crushed ALO-01 versus morphine sulfate solution (MSS) and placebo. | lld:pubmed |
| pubmed-article:19888784 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19888784 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19888784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19888784 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19888784 | pubmed:issn | 1173-2563 | lld:pubmed |
| pubmed-article:19888784 | pubmed:author | pubmed-author:SokolowskaMar... | lld:pubmed |
| pubmed-article:19888784 | pubmed:author | pubmed-author:StaufferJosep... | lld:pubmed |
| pubmed-article:19888784 | pubmed:author | pubmed-author:SellersEdward... | lld:pubmed |
| pubmed-article:19888784 | pubmed:author | pubmed-author:SetnikBeatric... | lld:pubmed |
| pubmed-article:19888784 | pubmed:author | pubmed-author:JohnsonFrankl... | lld:pubmed |
| pubmed-article:19888784 | pubmed:author | pubmed-author:RomachMyrosla... | lld:pubmed |
| pubmed-article:19888784 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19888784 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:19888784 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19888784 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19888784 | pubmed:pagination | 777-90 | lld:pubmed |
| pubmed-article:19888784 | pubmed:dateRevised | 2011-8-19 | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:meshHeading | pubmed-meshheading:19888784... | lld:pubmed |
| pubmed-article:19888784 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19888784 | pubmed:articleTitle | Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. | lld:pubmed |
| pubmed-article:19888784 | pubmed:affiliation | Alpharma Pharmaceuticals LLC, a wholly owned subsidiary of King Pharmaceuticals, Inc., Bridgewater, New Jersey, USA. beatrice.setnik@kingpharm.com | lld:pubmed |
| pubmed-article:19888784 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19888784 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19888784 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19888784 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
